Clinical Trial Detail

NCT ID NCT02034552
Title A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Bayer
Indications

prostate adenocarcinoma

Therapies

Prednisone

Radium Ra 223 dichloride

Enzalutamide

Abiraterone

Age Groups: adult

No variant requirements are available.